Influence of a short course of ritonavir used as booster in antiviral therapies against SARS-CoV-2 on the exposure of atorvastatin and rosuvastatin

Early antiviral treatment with nirmatrelvir/ritonavir is recommended for SARS-CoV-2-infected patients at high risk for severe courses. Such patients are usually chronically ill and susceptible to adverse drug interactions caused by ritonavir. We investigated the interactions of short-term low-dose r...

Full description

Bibliographic Details

Main Authors:	Krohmer, Evelyn (Author) , Rohr, Brit Silja (Author) , Stoll, Felicitas E. (Author) , Gümüs, Katja S. (Author) , Bergamino, Mariano (Author) , Mikus, Gerd (Author) , Sauter, Max (Author) , Burhenne, Jürgen (Author) , Weiß, Johanna (Author) , Meid, Andreas (Author) , Czock, David (Author) , Blank, Antje (Author) , Haefeli, Walter E. (Author)
Format:	Article (Journal)
Language:	English
Published:	2025
In:	Cardiovascular drugs and therapy Year: 2025, Volume: 39, Pages: 325–335
ISSN:	1573-7241
DOI:	10.1007/s10557-023-07538-w
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10557-023-07538-w Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s10557-023-07538-w
Author Notes:	Evelyn Krohmer, Brit Silja Rohr, Felicitas Stoll, Katja S. Gümüs, Mariano Bergamino, Gerd Mikus, Max Sauter, Jürgen Burhenne, Johanna Weiss, Andreas D. Meid, David Czock, Antje Blank, Walter E. Haefeli